Study of Finerenone in Subjects with Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease

What we are studying

The purpose of this study is to evaluate whether finerenone is effective and safe in reducing heart complications such as heart attacks, strokes and heart failure and in reducing heart related deaths in patients with type 2 diabetes mellitus and Diabetic Kidney Disease (DKD) in addition to regular therapy.

Who we are studying

  • Men and Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • Not Hispanic or Latino
  • Ages 18+

Eligibility Criteria

  • Diagnosed with type 2 diabetes
  • Diagnosis of DKD with at least one of the following criteria at Run-in and Screening visits:
    • Persistent high albuminuria 1 and presence of diabetic retinopathy OR persistent very high albuminuria 2.
  • Pretreated for at least 4 weeks prior to the Screening Visit with either ACEI or ARB (such as Losartan or Lisinopril) at maximal tolerated labeled dose
  • Preferably Without adjustments to dose or choice of agent or other treatment
  • Serum potassium less than or equal to 4.8 mmol/L.

What is involved

  • You will receive either finerenone (the active study drug) or a placebo

Compensation

Yes

Contact Information

Study Coordinator
Sheri Whittington
Email
smayer@wakehealth.edu
Phone
336-716-7754

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.